Logo
x

Search category

Subscribe Now

Sobi

Sobi Reports EMA’s Validation of MAA for Efanesoctocog Alfa to Treat Haemophilia A

Sobi Reports EMA’s Validation of MAA for Efanesoctocog Alfa to Treat Haemophilia A

  • May 19, 2023
Sobi to Acquire CTI BioPharma for ~$1.7B

Sobi to Acquire CTI BioPharma for ~$1.7B

  • May 11, 2023
PharmaShots' Key Highlights of First Quarter 2023

PharmaShots' Key Highlights of First Quarter 2023

  • April 3, 2023
Sobi and ADC Therapeutics Zynlonta (loncastuximab tesirine) Receives EC’s Conditional Marketing Authorisation for Diffuse Large B-Cell Lymphoma

Sobi and ADC Therapeutics Zynlonta (loncastuximab tesirine) Receives EC’s Conditional Marketing Authorisation for Diffuse Large B-...

  • December 21, 2022
Sobi and Sanofi Report Results of Efanesoctocog Alfa (BIVV001) in P-III (XTEND-1) study for the Treatment of Haemophilia A

Sobi and Sanofi Report Results of Efanesoctocog Alfa (BIVV001) in P-III (XTEND-1) study for the Treatment of Haemophilia A

  • March 9, 2022
Sobi’s Gamifant (emapalumab) Received Recommendation for Approval in China from CDE to Treat Adult and Paediatric Patients with Primary Haemophagocytic Lymphohistiocytosis

Sobi’s Gamifant (emapalumab) Received Recommendation for Approval in China from CDE to Treat Adult and Paediatric Patients with Pr...

  • February 28, 2022
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2023 PharmaShots - All Rights Reserved.